Coeptis Therapeutics (NASDAQ:COEP) Shares Set to Reverse Split on Tuesday, December 31st

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) are scheduled to reverse split on the morning of Tuesday, December 31st. The 1-20 reverse split was announced on Friday, December 27th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, December 30th.

Coeptis Therapeutics Price Performance

COEP stock traded down $0.03 during trading on Friday, hitting $0.18. The stock had a trading volume of 15,789,481 shares, compared to its average volume of 1,243,014. The stock has a market cap of $7.49 million, a price-to-earnings ratio of -0.63 and a beta of -0.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.40 and a current ratio of 0.40. The company’s 50 day moving average price is $0.19 and its two-hundred day moving average price is $0.22. Coeptis Therapeutics has a 1-year low of $0.13 and a 1-year high of $0.82.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.